Richard Nolan Townsend - 02 Nov 2023 Form 3 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
Chief Executive Officer, Director
Signature
/s/ Jenny Robertson, Attorney-in-Fact
Issuer symbol
LXEO
Transactions as of
02 Nov 2023
Transactions value $
$0
Form type
3
Filing time
02 Nov 2023, 21:42:46 UTC
Next filing
09 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LXEO Common Stock 127K 02 Nov 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LXEO Employee Stock Option (right to buy) 02 Nov 2023 Common Stock 154K $2.33 Direct F1
holding LXEO Employee Stock Option (right to buy) 02 Nov 2023 Common Stock 519K $4.87 Direct F2
holding LXEO Employee Stock Option (right to buy) 02 Nov 2023 Common Stock 106K $11.02 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying the option vested on November 21, 2021, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F2 25% of the shares underlying the option vested on August 11, 2022, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F3 25% of the shares underlying the option shall vest on August 22, 2024, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney